RAC 2.60% $1.58 race oncology ltd

Ann: Bisantrene Phase 2 AML Trial Successful Concludes, page-37

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 2,063 Posts.
    lightbulb Created with Sketch. 359
    It was investigator lead from before the company pivot and using RC110. If there were to be a P3 trial for it, it would need to be with the same formulation. I would assume these announcement are more a formality on races part due to compliance.

    The upcoming AML trial will be using rc220, which will be relevant to race's pipeline, even if there may be no current funding strategies for further trials for AML.
 
watchlist Created with Sketch. Add RAC (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.